<DOC>
	<DOCNO>NCT00601575</DOCNO>
	<brief_summary>The objective study assess bioequivalence two Roxane lithium carbonate 450 mg extend release tablet formulation compare GlaxoSmithKline 's Eskalith CR 450 mg extend release tablet feed condition use single-dose , randomize , three-treatment , three-period , six-sequence crossover design .</brief_summary>
	<brief_title>Bioequivalency Study 450 mg Lithium Carbonate Under Fed Conditions</brief_title>
	<detailed_description />
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lithium Carbonate</mesh_term>
	<criteria>No clinically significant abnormal finding physical examination , medical history , clinical laboratory result screen . Participation clinicl trial within 30 day prior study initiation . Positive test HIV , Hepatitis B , Hepatitis C. Treatment know enzyme alter drug .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>